PTC Retained Earnings from 2010 to 2025

PTCT Stock

USD 45.88 0.27 0.59%

PTC Therapeutics Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that PTC Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2012-12-31

Previous Quarter

-3.5 B

Current Value

-3.6 B

Quarterly Volatility

1 B

Yuan Drop

Covid

Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 156 M, Total Revenue of 1.1 B or Research Development of 804.9 M, as well as many indicators such as Price To Sales Ratio of 2.4, Dividend Yield of 0.0 or Days Sales Outstanding of 51.74. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.

Check out the analysis of PTC Therapeutics Correlation against competitors.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

Latest PTC Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of PTC Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. PTC Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PTC Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (3.28 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

PTC Retained Earnings Regression Statistics

	Arithmetic Mean	(1,326,968,691)
	Geometric Mean	914,035,892
	Coefficient Of Variation	(81.82)
	Mean Deviation	933,531,655
	Median	(814,108,000)
	Standard Deviation	1,085,678,543
	Sample Variance	1178697.9T
	Range	3B
	R-Value	(0.94)
	Mean Square Error	144360T
	R-Squared	0.89
	Slope	(214,609,282)
	Total Sum of Squares	17680468.5T

PTC Retained Earnings History

	2025	-2.8 B
	2024	-3 B
	2023	-3.3 B
	2022	-2.7 B
	2021	-2.1 B
	2020	-1.6 B
	2019	-1.2 B

Other Fundumenentals of PTC Therapeutics

Retained Earnings Total Equity

PTC Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.37	0.57	0.72	0.64	0.93	0.81	0.21	0.6	-0.9	0.89	0.95	0.62	0.88	-0.87	0.94	0.86	0.5	0.76	0.85	0.91
Total Stockholder Equity	-0.37		0.04	-0.82	0.18	-0.69	-0.6	0.03	-0.86	0.7	-0.71	-0.49	-0.71	-0.24	0.68	-0.38	-0.73	-0.72	-0.58	-0.23	-0.63
Accounts Payable	0.57	0.04		0.07	0.48	0.42	0.57	0.4	-0.06	-0.49	0.46	0.41	0.13	0.64	-0.5	0.63	0.39	0.11	-0.02	0.36	0.46
Long Term Debt	0.72	-0.82	0.07		0.16	0.9	0.66	-0.13	0.97	-0.86	0.88	0.85	0.88	0.57	-0.79	0.65	0.91	0.79	0.92	0.59	0.82
Short Term Investments	0.64	0.18	0.48	0.16		0.42	0.43	0.36	0.07	-0.36	0.27	0.62	0.24	0.55	-0.26	0.58	0.27	0.32	0.35	0.82	0.51
Total Liab	0.93	-0.69	0.42	0.9	0.42		0.86	0.14	0.82	-0.97	0.97	0.94	0.78	0.78	-0.94	0.87	0.96	0.69	0.84	0.75	0.96
Property Plant Equipment	0.81	-0.6	0.57	0.66	0.43	0.86		0.59	0.55	-0.86	0.85	0.74	0.74	0.7	-0.87	0.78	0.78	0.61	0.55	0.55	0.86
Current Deferred Revenue	0.21	0.03	0.4	-0.13	0.36	0.14	0.59		-0.24	-0.13	0.1	0.04	0.19	0.17	-0.2	0.21	-0.04	0.11	-0.14	0.07	0.18
Net Debt	0.6	-0.86	-0.06	0.97	0.07	0.82	0.55	-0.24		-0.78	0.81	0.76	0.79	0.43	-0.71	0.53	0.85	0.8	0.87	0.53	0.74
Retained Earnings	-0.9	0.7	-0.49	-0.86	-0.36	-0.97	-0.86	-0.13	-0.78		-0.98	-0.9	-0.76	-0.83	0.97	-0.9	-0.96	-0.65	-0.76	-0.69	-0.94
Net Receivables	0.89	-0.71	0.46	0.88	0.27	0.97	0.85	0.1	0.81	-0.98		0.88	0.77	0.79	-0.97	0.86	0.97	0.63	0.78	0.62	0.92
Total Current Assets	0.95	-0.49	0.41	0.85	0.62	0.94	0.74	0.04	0.76	-0.9	0.88		0.75	0.82	-0.8	0.87	0.89	0.69	0.88	0.88	0.92
Short Term Debt	0.62	-0.71	0.13	0.88	0.24	0.78	0.74	0.19	0.79	-0.76	0.77	0.75		0.54	-0.66	0.56	0.74	0.83	0.78	0.46	0.72
Common Stock	0.88	-0.24	0.64	0.57	0.55	0.78	0.7	0.17	0.43	-0.83	0.79	0.82	0.54		-0.79	0.95	0.73	0.37	0.58	0.72	0.82
Net Tangible Assets	-0.87	0.68	-0.5	-0.79	-0.26	-0.94	-0.87	-0.2	-0.71	0.97	-0.97	-0.8	-0.66	-0.79		-0.88	-0.92	-0.52	-0.67	-0.59	-0.9
Capital Surpluse	0.94	-0.38	0.63	0.65	0.58	0.87	0.78	0.21	0.53	-0.9	0.86	0.87	0.56	0.95	-0.88		0.83	0.44	0.64	0.81	0.92
Long Term Debt Total	0.86	-0.73	0.39	0.91	0.27	0.96	0.78	-0.04	0.85	-0.96	0.97	0.89	0.74	0.73	-0.92	0.83		0.65	0.81	0.67	0.93
Short Long Term Debt	0.5	-0.72	0.11	0.79	0.32	0.69	0.61	0.11	0.8	-0.65	0.63	0.69	0.83	0.37	-0.52	0.44	0.65		0.68	0.54	0.67
Net Invested Capital	0.76	-0.58	-0.02	0.92	0.35	0.84	0.55	-0.14	0.87	-0.76	0.78	0.88	0.78	0.58	-0.67	0.64	0.81	0.68		0.74	0.78
Net Working Capital	0.85	-0.23	0.36	0.59	0.82	0.75	0.55	0.07	0.53	-0.69	0.62	0.88	0.46	0.72	-0.59	0.81	0.67	0.54	0.74		0.82
Capital Stock	0.91	-0.63	0.46	0.82	0.51	0.96	0.86	0.18	0.74	-0.94	0.92	0.92	0.72	0.82	-0.9	0.92	0.93	0.67	0.78	0.82

Click cells to compare fundamentals

About PTC Therapeutics Financial Statements

PTC Therapeutics shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-3 B	-2.8 B
Retained Earnings Total Equity	-2.4 B	-2.3 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC